Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.

Int J Colorectal Dis · 2013 · PMC3587684 · PMID 22983756

Europe PMC DOI

hedged sentence

0.0537

closest p · 1.1× alpha

0.0537

boldest claim

The sentences

borderline significantp = 0.0537so close (0.05 < p ≤ 0.1)

For Ki-67, analysis of variance demonstrated a significant effect for sorafenib ( p = 0.0101), and for 5-FU + sorafenib interaction ( p = 0.0049), the 5-FU main effect was borderline significant ( p = 0.0537) as compared to the control group.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.